BOGUSLAW GLUSZAK: Open Payments
NPI 1689632994 · BOLIVAR, MO. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,588 in 97 payments from 11 companies in 2025. Trend: 2023 $195 · 2024 $2,577 · 2025 $1,588
Food & beverage: $1,588
| Company | Payments | Amount |
|---|---|---|
| Neurocrine BioSciences, Inc. | 20 | $381 |
| Teva Pharmaceuticals USA, Inc. | 36 | $255 |
| ABBVIE INC. | 10 | $213 |
| Vanda Pharmaceuticals Inc. | 5 | $171 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 7 | $152 |
| Janssen Pharmaceuticals, Inc | 4 | $115 |
| E.R. Squibb & Sons, L.L.C. | 5 | $114 |
| Alkermes, Inc. | 4 | $70 |
| Supernus Pharmaceuticals, Inc. | 3 | $54 |
| Otsuka America Pharmaceutical, Inc. | 2 | $33 |
Products named: INGREZZA, VRAYLAR, AUSTEDO XR, CAPLYTA, HETLIOZ, COBENFY, INVEGA, ARISTADA.
Industry payments across MO — which companies pay providers there.
